Source: International Congress 2014 – Intervening in allergic asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Busse, B. Trazskoma, T. Omachi, J. Canvin, K. Rosén, B. Chipps, A. Luskin, P. Solari (Madison, South San Francisco, Sacramento, United States Of America; Horsham, United Kingdom). Evaluating omalizumab persistency of response after long-term therapy (XPORT). Eur Respir J 2014; 44: Suppl. 58, 3485

Member's Comments

No comment yet.

Related content which might interest you: Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 The impact of sublingual allergen-specific therapy on asthma control and quality of life Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Features of asthma treatment while pregnancy Source: International Congress 2014 – Asthma: clinical problems Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Serious asthma exacerbations in a hospital setting Source: International Congress 2014 – Asthma: clinical problems Year: 2014 LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Development of binary forecast models of asthma exacerbation: Asthma index Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015